LEASE THE COVE AT OYSTER POINT HCP OYSTER POINT III LLC, a Delaware limited liability company as Landlord, and DENALI THERAPEUTICS INC., a Delaware corporation, as Tenant.Lease • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (“Landlord”), and DENALI THERAPEUTICS INC., a Delaware corporation (“Tenant”).
November 10, 2017 Steve Krognes c/o Denali Therapeutics Inc. South San Francisco, CA 94080 Re: Confirmatory Employment Letter Dear Steve:Letter Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances)
This letter agreement (the “Agreement”) is entered into between Denali Therapeutics Inc. (the “Company”) and Steve Krognes. This Agreement is effective as of the date you sign this letter, as indicated below. The purpose of this Agreement is to confirm the current terms and conditions of your employment with the Company.
LICENSE AND COLLABORATION AGREEMENT among F-STAR GAMMA LIMITED, F-STAR BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGSGES.M.B.H, F-STAR BIOTECHNOLOGY LIMITED, and DENALI THERAPEUTICS INC. Dated as of 24 August 2016License and Collaboration Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • England
THIS LICENSE AND COLLABORATION AGREEMENT is made and entered into effective as of 24 August 2016 (the “Effective Date”) by and between
EXCLUSIVE LICENSE AGREEMENT BETWEEN GENENTECH, INC. AND DENALI THERAPEUTICS INC. AS OF JUNE 17, 2016Exclusive License Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement (“Agreement”) is made and entered into as of the 17th day of June, 2016 (the “Effective Date”) by and between Denali Therapeutics Inc., a Delaware corporation with a principal place of business at 201 Gateway Blvd., South San Francisco, CA 94080 (“Denali”) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“Genentech”). Denali and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.”
INVESTORS’ RIGHTS AGREEMENTRights Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 8th day of May, 2015, by and among Denali Therapeutics Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
Development & Manufacturing Services Agreement (the “Agreement”)Services Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;
